These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 31964274)
1. Mitigating temozolomide resistance in glioblastoma via DNA damage-repair inhibition. Sorribes IC; Handelman SK; Jain HV J R Soc Interface; 2020 Jan; 17(162):20190722. PubMed ID: 31964274 [TBL] [Abstract][Full Text] [Related]
2. GBP3-STING interaction in glioblastoma coordinates autophagy, anti-oxidative, and DNA repair programs in response to temozolomide. Ma J; Wang Z; Chen CC; Li M Oncotarget; 2023 May; 14():483-484. PubMed ID: 37204260 [No Abstract] [Full Text] [Related]
3. Chip-based analysis of exosomal mRNA mediating drug resistance in glioblastoma. Shao H; Chung J; Lee K; Balaj L; Min C; Carter BS; Hochberg FH; Breakefield XO; Lee H; Weissleder R Nat Commun; 2015 May; 6():6999. PubMed ID: 25959588 [TBL] [Abstract][Full Text] [Related]
4. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma. Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952 [TBL] [Abstract][Full Text] [Related]
5. PARP-mediated PARylation of MGMT is critical to promote repair of temozolomide-induced O6-methylguanine DNA damage in glioblastoma. Wu S; Li X; Gao F; de Groot JF; Koul D; Yung WKA Neuro Oncol; 2021 Jun; 23(6):920-931. PubMed ID: 33433610 [TBL] [Abstract][Full Text] [Related]
6. Acquired temozolomide resistance in MGMT-deficient glioblastoma cells is associated with regulation of DNA repair by DHC2. Yi GZ; Huang G; Guo M; Zhang X; Wang H; Deng S; Li Y; Xiang W; Chen Z; Pan J; Li Z; Yu L; Lei B; Liu Y; Qi S Brain; 2019 Aug; 142(8):2352-2366. PubMed ID: 31347685 [TBL] [Abstract][Full Text] [Related]
7. Hegi ME; Genbrugge E; Gorlia T; Stupp R; Gilbert MR; Chinot OL; Nabors LB; Jones G; Van Criekinge W; Straub J; Weller M Clin Cancer Res; 2019 Mar; 25(6):1809-1816. PubMed ID: 30514777 [TBL] [Abstract][Full Text] [Related]
8. DNA repair in personalized brain cancer therapy with temozolomide and nitrosoureas. Kaina B; Christmann M DNA Repair (Amst); 2019 Jun; 78():128-141. PubMed ID: 31039537 [TBL] [Abstract][Full Text] [Related]
9. Glycogen synthase kinase 3β inhibition sensitizes human glioblastoma cells to temozolomide by affecting O6-methylguanine DNA methyltransferase promoter methylation via c-Myc signaling. Pyko IV; Nakada M; Sabit H; Teng L; Furuyama N; Hayashi Y; Kawakami K; Minamoto T; Fedulau AS; Hamada J Carcinogenesis; 2013 Oct; 34(10):2206-17. PubMed ID: 23715499 [TBL] [Abstract][Full Text] [Related]
10. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700 [TBL] [Abstract][Full Text] [Related]
11. Novel predictive epigenetic signature for temozolomide in non-G-CIMP glioblastomas. Yin AA; He YL; Etcheverry A; Liu YH; Aubry M; Barnholtz-Sloan J; Liu BL; Mosser J; Lu ZF; Zhang X Clin Epigenetics; 2019 May; 11(1):76. PubMed ID: 31088577 [TBL] [Abstract][Full Text] [Related]
13. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT. Fukushima T; Takeshima H; Kataoka H Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445 [TBL] [Abstract][Full Text] [Related]
14. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Chakravarti A; Erkkinen MG; Nestler U; Stupp R; Mehta M; Aldape K; Gilbert MR; Black PM; Loeffler JS Clin Cancer Res; 2006 Aug; 12(15):4738-46. PubMed ID: 16899625 [TBL] [Abstract][Full Text] [Related]
15. The histone demethylase KDM5A is a key factor for the resistance to temozolomide in glioblastoma. Banelli B; Carra E; Barbieri F; Würth R; Parodi F; Pattarozzi A; Carosio R; Forlani A; Allemanni G; Marubbi D; Florio T; Daga A; Romani M Cell Cycle; 2015; 14(21):3418-29. PubMed ID: 26566863 [TBL] [Abstract][Full Text] [Related]
16. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication. Aghi M; Rabkin S; Martuza RL J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370 [TBL] [Abstract][Full Text] [Related]
17. Developing a clinically relevant radiosensitizer for temozolomide-resistant gliomas. Minea RO; Duc TC; Swenson SD; Cho HY; Huang M; Hartman H; Hofman FM; Schönthal AH; Chen TC PLoS One; 2020; 15(9):e0238238. PubMed ID: 32881880 [TBL] [Abstract][Full Text] [Related]
18. Endoplasmic reticulum stress-inducing drugs sensitize glioma cells to temozolomide through downregulation of MGMT, MPG, and Rad51. Xipell E; Aragón T; Martínez-Velez N; Vera B; Idoate MA; Martínez-Irujo JJ; Garzón AG; Gonzalez-Huarriz M; Acanda AM; Jones C; Lang FF; Fueyo J; Gomez-Manzano C; Alonso MM Neuro Oncol; 2016 Aug; 18(8):1109-19. PubMed ID: 26951384 [TBL] [Abstract][Full Text] [Related]
19. Preconditioning with INC280 and LDK378 drugs sensitizes MGMT-unmethylated glioblastoma to temozolomide: Pre-clinical assessment. Das A; Alshareef M; Porto GBF; Infinger LK; Vandergrift WA; Lindhorst SM; Varma AK; Patel SJ; Cachia D J Neurol Sci; 2020 Nov; 418():117102. PubMed ID: 32866816 [TBL] [Abstract][Full Text] [Related]
20. Lnc-TALC promotes O Wu P; Cai J; Chen Q; Han B; Meng X; Li Y; Li Z; Wang R; Lin L; Duan C; Kang C; Jiang C Nat Commun; 2019 May; 10(1):2045. PubMed ID: 31053733 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]